Passage Bio Inc (PASG)

Apr 30, 2025

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus

Apr 30, 2025

Apr 29, 2025

Fierce Biotech Layoff Tracker 2025: Entrada cuts 20% of workforce; Ono lays off 83 staffers - Fierce Biotech

Apr 29, 2025

Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia

Apr 17, 2025

Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 09, 2025

Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World

Apr 09, 2025

Apr 07, 2025

PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025

Apr 03, 2025

GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com

Apr 03, 2025

Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 - Investing.com

Mar 31, 2025

Mar 28, 2025

Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace

Mar 28, 2025

Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025

Mar 27, 2025

Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com

Mar 27, 2025

Mar 25, 2025

Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech

Mar 25, 2025

Mar 23, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo

Mar 23, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025

Mar 16, 2025

Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo

Mar 16, 2025

Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo

Mar 13, 2025

Mar 09, 2025

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN

Mar 09, 2025

Mar 08, 2025

Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World

Mar 08, 2025

Mar 07, 2025

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq

Mar 07, 2025

Mar 07, 2025

FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World

Mar 07, 2025

Mar 05, 2025

Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com

Mar 05, 2025

Mar 05, 2025

Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World

Mar 05, 2025

Mar 04, 2025

Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks

Mar 04, 2025

Mar 04, 2025

Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks

Mar 04, 2025

Mar 04, 2025

Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India

Mar 04, 2025

Mar 04, 2025

Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 04, 2025

Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India

Mar 04, 2025

Mar 04, 2025

Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa

Mar 04, 2025